Plus, the ECB cut rates, SmileDirectClub debuted, and Groupon might be about to make an offer for Yelp.
Read MorePlus, Trump bashed the Fed on Twitter again, China just exempted some products from tariffs, and shares of GameStop are tanking.
Read MorePlus, Moody’s downgraded Ford to junk, China’s Huawei dropped a lawsuit against the U.S., WeWork is moving ahead with its IPO, and Wendy’s is bringing back breakfast.
Read MoreProgress on the trade front has given the market a new set of momentum over the past couple of weeks – enough that the major indices are nearing the all-time highs they set at the end of July. Even so, the unpredictability associated with tariff news and the trade war itself has resulted in a […]
Read MorePlus, the Labor Department’s job’s report, the Trump Administration’s plans to release Fannie Mae and Freddie Mac from federal control, and why shares of Lululemon and DocuSign are surging higher.
Read MoreAlexion Pharmaceuticals Inc. (ALXN) has had an abysmal run over just the last two sessions. While Friday saw the biotech — known for developing Soliris, a treatment for atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH) — become the S&P 500’s second-worst performer that session, the stock outdid itself during Tuesday’s session by […]
Read MoreThe conversation about interest rates rages on, while the dollar strengthens, and big tech gets a new warning.
Read MoreCEOs from 181 major corporations signed a new “purpose of a corporation” definition statement. Also, stocks are climbing, gold is falling, and investors are speculating on the Fed.
Read MoreTrade Setup Buy Target $1.70 Sell Target $2.00 Stop Loss $1.23 Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ala-Scalp and Triderm, which are used […]
Read MoreThe yield curve is inverting, and bank stocks and department store stocks are crashing. Welcome to Wednesday.
Read MoreBuy Target $1.22 Sell Target $1.41 Trailing Stop 20% BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company’s lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for […]
Read MoreTrade Setup Buy Target $2.80 Sell Target 1 $3.34 Trailing Stop 20% Sell Target 2 $3.72 Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized […]
Read MoreTrade Setup Buy Target $4.26 Sell Target 1 $5.50 Trailing Stop 20% Sell Target 2 $6.90 Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company’s lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in […]
Read MoreBiotechs are headed for a big rally, and analysts say these 3 stocks in the sector could see double-digit upside ahead.
Read MoreOne of the year’s biggest merger announcements sent shockwaves through the U.S. pharmaceutical sector on Tuesday when Humira drugmaker AbbVie Inc. (ABBV) struck a deal to acquire Botox producer Allergan Plc. (AGN). Investors reacted strongly to the news, making ABBV and AGN the market’s single biggest loser and winner, respectively. After the deal closes, AbbVie […]
Read More